Skip to main content
NCBI home page
Gut logoLink to Gut
. 1997 Apr;40(4):475–480. doi: 10.1136/gut.40.4.475

In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.

J M Reimund 1, S Dumont 1, C D Muller 1, J S Kenney 1, M Kedinger 1, R Baumann 1, P Poindron 1, B Duclos 1
PMCID: PMC1027121  PMID: 9176074

Abstract

BACKGROUND: Inflammatory cytokines, including tumour necrosis factor-alpha (TNF-alpha) and interleukin (IL)-1 beta, have been implicated as primary mediators of intestinal inflammation in inflammatory bowel disease. AIM: To investigate the in vitro effects of oxpentifylline (pentoxifylline; PTX; a phosphodiesterase inhibitor) on inflammatory cytokine production (1) by peripheral mononuclear cells (PBMCs) and (2) by inflamed intestinal mucosa cultures from patients with Crohn's disease and patients with ulcerative colitis. METHODS: PBMCs and mucosal biopsy specimens were cultured for 24 hours in the absence or presence of PTX (up to 100 micrograms/ml), and the secretion of TNF-alpha, IL-1 beta, IL-6, and IL-8 determined by enzyme linked immunosorbent assays (ELISAs). RESULTS: PTX inhibited the release of TNF-alpha by PBMCs from patients with inflammatory bowel disease and the secretion of TNF-alpha and IL-1 beta by organ cultures of inflamed mucosa from the same patients. Secretion of TNF-alpha by PBMCs was inhibited by about 50% at a PTX concentration of 25 micrograms/ml (IC50). PTX was equally potent in cultures from controls, patients with Crohn's disease, and those with ulcerative colitis. The concentrations of IL-6 and IL-8 were not significantly modified in PBMCs, but IL-6 increased slightly in organ culture supernatants. CONCLUSIONS: PTX or more potent related compounds may represent a new family of cytokine inhibitors, potentially interesting for treatment of inflammatory bowel disease.

Full text

PDF
475

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauditz J., Rückert Y., Raedler A., Nikolaus S., Lochs H., Schreiber S. Tumour necrosis factor inhibition by oxpentifylline and intestinal inflammation in Crohn's disease. Lancet. 1995 Jun 3;345(8962):1445–1445. doi: 10.1016/s0140-6736(95)92635-6. [DOI] [PubMed] [Google Scholar]
  2. Bessler H., Gilgal R., Djaldetti M., Zahavi I. Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukoc Biol. 1986 Dec;40(6):747–754. doi: 10.1002/jlb.40.6.747. [DOI] [PubMed] [Google Scholar]
  3. Betz M., Fox B. S. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol. 1991 Jan 1;146(1):108–113. [PubMed] [Google Scholar]
  4. Braegger C. P., Nicholls S., Murch S. H., Stephens S., MacDonald T. T. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992 Jan 11;339(8785):89–91. doi: 10.1016/0140-6736(92)90999-j. [DOI] [PubMed] [Google Scholar]
  5. Breese E., Braegger C. P., Corrigan C. J., Walker-Smith J. A., MacDonald T. T. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology. 1993 Jan;78(1):127–131. [PMC free article] [PubMed] [Google Scholar]
  6. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  7. Cominelli F., Nast C. C., Duchini A., Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology. 1992 Jul;103(1):65–71. doi: 10.1016/0016-5085(92)91096-m. [DOI] [PubMed] [Google Scholar]
  8. DeVault G. A., Jr, Kohan D. E., Nelson E. W., Holman J. M., Jr The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3. Transplantation. 1994 Feb 27;57(4):532–540. [PubMed] [Google Scholar]
  9. Derkx B., Taminiau J., Radema S., Stronkhorst A., Wortel C., Tytgat G., van Deventer S. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet. 1993 Jul 17;342(8864):173–174. doi: 10.1016/0140-6736(93)91375-v. [DOI] [PubMed] [Google Scholar]
  10. Endres S., Fülle H. J., Sinha B., Stoll D., Dinarello C. A., Gerzer R., Weber P. C. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells. Immunology. 1991 Jan;72(1):56–60. [PMC free article] [PubMed] [Google Scholar]
  11. Han J., Thompson P., Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990 Jul 1;172(1):391–394. doi: 10.1084/jem.172.1.391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Henderson B., Blake S. Therapeutic potential of cytokine manipulation. Trends Pharmacol Sci. 1992 Apr;13(4):145–152. doi: 10.1016/0165-6147(92)90052-8. [DOI] [PubMed] [Google Scholar]
  13. Kenney J. S., Masada M. P., Eugui E. M., Delustro B. M., Mulkins M. A., Allison A. C. Monoclonal antibodies to human recombinant interleukin 1 (IL 1)beta: quantitation of IL 1 beta and inhibition of biological activity. J Immunol. 1987 Jun 15;138(12):4236–4242. [PubMed] [Google Scholar]
  14. Mazlam M. Z., Hodgson H. J. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut. 1992 Jun;33(6):773–778. doi: 10.1136/gut.33.6.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mitsuyama K., Sasaki E., Toyonaga A., Ikeda H., Tsuruta O., Irie A., Arima N., Oriishi T., Harada K., Fujisaki K. Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion. 1991;50(2):104–111. doi: 10.1159/000200747. [DOI] [PubMed] [Google Scholar]
  16. Mitsuyama K., Toyonaga A., Sasaki E., Watanabe K., Tateishi H., Nishiyama T., Saiki T., Ikeda H., Tsuruta O., Tanikawa K. IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1994 Jun;96(3):432–436. doi: 10.1111/j.1365-2249.1994.tb06047.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Neuner P., Klosner G., Schauer E., Pourmojib M., Macheiner W., Grünwald C., Knobler R., Schwarz A., Luger T. A., Schwarz T. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology. 1994 Oct;83(2):262–267. [PMC free article] [PubMed] [Google Scholar]
  18. Novak T. J., Rothenberg E. V. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9353–9357. doi: 10.1073/pnas.87.23.9353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ollivier V., Ternisien C., Vu T., Hakim J., de Prost D. Pentoxifylline inhibits the expression of tissue factor mRNA in endotoxin-activated human monocytes. FEBS Lett. 1993 May 17;322(3):231–234. doi: 10.1016/0014-5793(93)81576-l. [DOI] [PubMed] [Google Scholar]
  20. Peterson T. C., Isbrucker R. A., Hooper M. L. In vitro effect of platelet-derived growth factor on fibroproliferation and effect of cytokine antagonists. Immunopharmacology. 1994 Nov-Dec;28(3):259–270. doi: 10.1016/0162-3109(94)90061-2. [DOI] [PubMed] [Google Scholar]
  21. Ramani M., Khechai F., Ollivier V., Ternisien C., Bridey F., Hakim J., de Prost D. Interleukin-10 and pentoxifylline inhibit C-reactive protein-induced tissue factor gene expression in peripheral human blood monocytes. FEBS Lett. 1994 Dec 12;356(1):86–88. doi: 10.1016/0014-5793(94)01236-9. [DOI] [PubMed] [Google Scholar]
  22. Reimund J. M., Wittersheim C., Dumont S., Muller C. D., Baumann R., Poindron P., Duclos B. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol. 1996 May;16(3):144–150. doi: 10.1007/BF01540912. [DOI] [PubMed] [Google Scholar]
  23. Reimund J. M., Wittersheim C., Dumont S., Muller C. D., Kenney J. S., Baumann R., Poindron P., Duclos B. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut. 1996 Nov;39(5):684–689. doi: 10.1136/gut.39.5.684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Reinecker H. C., Steffen M., Witthoeft T., Pflueger I., Schreiber S., MacDermott R. P., Raedler A. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993 Oct;94(1):174–181. doi: 10.1111/j.1365-2249.1993.tb05997.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rott O., Cash E., Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol. 1993 Aug;23(8):1745–1751. doi: 10.1002/eji.1830230802. [DOI] [PubMed] [Google Scholar]
  26. Schandené L., Vandenbussche P., Crusiaux A., Alègre M. L., Abramowicz D., Dupont E., Content J., Goldman M. Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells. Immunology. 1992 May;76(1):30–34. [PMC free article] [PubMed] [Google Scholar]
  27. Sher M. E., D'Angelo A. J., Stein T. A., Bailey B., Burns G., Wise L. Cytokines in Crohn's colitis. Am J Surg. 1995 Jan;169(1):133–136. doi: 10.1016/s0002-9610(99)80121-4. [DOI] [PubMed] [Google Scholar]
  28. Strieter R. M., Remick D. G., Ward P. A., Spengler R. N., Lynch J. P., 3rd, Larrick J., Kunkel S. L. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988 Sep 30;155(3):1230–1236. doi: 10.1016/s0006-291x(88)81271-3. [DOI] [PubMed] [Google Scholar]
  29. TRUELOVE S. C., WITTS L. J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041–1048. doi: 10.1136/bmj.2.4947.1041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tannenbaum C. S., Hamilton T. A. Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J Immunol. 1989 Feb 15;142(4):1274–1280. [PubMed] [Google Scholar]
  31. Thanhäuser A., Reiling N., Böhle A., Toellner K. M., Duchrow M., Scheel D., Schlüter C., Ernst M., Flad H. D., Ulmer A. J. Pentoxifylline: a potent inhibitor of IL-2 and IFN-gamma biosynthesis and BCG-induced cytotoxicity. Immunology. 1993 Sep;80(1):151–156. [PMC free article] [PubMed] [Google Scholar]
  32. Waage A., Sørensen M., Størdal B. Differential effect of oxpentifylline on tumour necrosis factor and interleukin-6 production. Lancet. 1990 Mar 3;335(8688):543–543. doi: 10.1016/0140-6736(90)90779-5. [DOI] [PubMed] [Google Scholar]
  33. Wardle T. D., Hall L., Turnberg L. A. Use of coculture of colonic mucosal biopsies to investigate the release of eicosanoids by inflamed and uninflamed mucosa from patients with inflammatory bowel disease. Gut. 1992 Dec;33(12):1644–1651. doi: 10.1136/gut.33.12.1644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Zhang Y., Lin J. X., Vilcek J. Synthesis of interleukin 6 (interferon-beta 2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. J Biol Chem. 1988 May 5;263(13):6177–6182. [PubMed] [Google Scholar]
  35. van Dullemen H. M., van Deventer S. J., Hommes D. W., Bijl H. A., Jansen J., Tytgat G. N., Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995 Jul;109(1):129–135. doi: 10.1016/0016-5085(95)90277-5. [DOI] [PubMed] [Google Scholar]
  36. van Hees P. A., van Elteren P. H., van Lier H. J., van Tongeren J. H. An index of inflammatory activity in patients with Crohn's disease. Gut. 1980 Apr;21(4):279–286. doi: 10.1136/gut.21.4.279. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES